Noxopharm (ASX: NOX) announces that it has received $3.264M cash rebate as part of the Federal Government’s R&D Tax Incentive Scheme.
Graham Kelly Ph.D., Noxopharm Chief Executive Officer, said, “This rebate means that we will finish the calendar year with just over $10M in cash, putting the Company in a solid financial position as we enter 2019 and a busy clinical agenda. Having recently had confirmation of the anti-cancer potential of Veyonda as both a
radio-enhancer and chemo-enhancer, these funds will go towards expediting the clinical development of Veyonda as it enters its final stages of development next year.”
For more information, download the attached PDF.
Download this document
